Christopher Skedgel (Chris Skedgel)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 13

Top Venues

PharmacoEconomics

PharmacoEconomics - open

Patient preference and adherence

MDM policy & practice

Office Of Health Economics

University of Sheffield (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Office Of Health Economics

United Kingdom

Associate Director

IQVIA

United Kingdom

Senior Consultant :: HEOR

University of East Anglia Jan 19 2015 - Jan 31 2018

United Kingdom

Senior Lecturer in Applied Health Economics :: Medical School

Capital Health

Canada

Health Economist :: Atlantic Clinical Cancer Research Unit

Dalhousie University Faculty of Medicine

Canada

Research Health Economist :: Medicine

Dalhousie University Faculty of Medicine

Canada

Senior Research Analyst :: Community Health & Epidemiology

Education History

University of Sheffield

United Kingdom

PHD :: School of Health & Related Research

Publications

Christopher Skedgel, David John Mott, Saif Elayan, Angela Cramb
A Longer Life or a Quality Death? A Discrete Choice Experiment to Estimate the Relative Importance of Different Aspects of End-of-Life Care in the United Kingdom. MDM policy & practice 9 (1) (2024)
Christopher Skedgel, David John Mott, Saif Elayan, Angela Cramb
A Longer Life or a Quality Death? A Discrete Choice Experiment to Estimate the Relative Importance of Different Aspects of End-of-Life Care in the United Kingdom. MDM policy & practice 9 (1) (2024)
David John Mott, Jake Hitch, Samantha Nier, Zack Pemberton-Whiteley, Christopher Skedgel
Patient Preferences for Treatment in Relapsed/Refractory Acute Leukemia in the United Kingdom: A Discrete Choice Experiment. Patient preference and adherence 18 (2024)
David John Mott, Jake Hitch, Samantha Nier, Zack Pemberton-Whiteley, Christopher Skedgel
Patient Preferences for Treatment in Relapsed/Refractory Acute Leukemia in the United Kingdom: A Discrete Choice Experiment. Patient preference and adherence 18 (2024)
David John Mott, Hannah Schirrmacher, Hareth Al-Janabi, Sophie Guest, Rebekah Pennington, Nicolas Scheuer, Koonal Kirit Shah, Christopher Skedgel
Modelling Spillover Effects on Informal Carers: The Carer QALY Trap. PharmacoEconomics (2023)
Christopher Skedgel, Patricia Cubi-Molla, David Mott, Sofia Gameiro, Jacky Boivin, Hareth Al-Janabi, John Brazier, Marie Markert, Fredrik L Andersson, Mireia Jofre-Bonet
Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility. PharmacoEconomics - open (2023)
Christopher Skedgel, Patricia Cubi-Molla, David Mott, Sofia Gameiro, Jacky Boivin, Hareth Al-Janabi, John Brazier, Marie Markert, Fredrik L Andersson, Mireia Jofre-Bonet
Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility. PharmacoEconomics - open (2023)
Christopher Skedgel, Eleanor Ralphs, Elaine Finn, Marie Markert, Carl Samuelsen, Jennifer A Whitty
How Do People with Experience of Infertility Value Different Aspects of Assistive Reproductive Therapy? Results from a Multi-Country Discrete Choice Experiment. The patient 15 (4) (2021)
Christopher Skedgel
Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain. PharmacoEconomics 40 (Suppl 1) (2021)
Kyann Zhang, Gayathri Kumar, Christopher Skedgel
Towards a New Understanding of Unmet Medical Need. Applied health economics and health policy 19 (6) (2021)
Christopher Skedgel, Eleanor Ralphs, Elaine Finn, Jennifer A Whitty, Marie Markert, Carl Samuelsen
Is the public supportive and willing to pay for a national assistive reproductive therapies programme? Results from a multicountry survey. BMJ open 11 (3) (2021)
Christopher Skedgel, Wiesława Dominika Wranik, Min Hu
The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017. PharmacoEconomics 36 (4) (2019)
Wiesława Dominika Wranik, Christopher Skedgel, Min Hu
Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders. Expert review of pharmacoeconomics & outcomes research 19 (1) (2018)
Christopher Skedgel, Daniel Rayson, Tallal Younis
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 24 (1) (2015)

Christopher Skedgel.css-eqlu8i{font-size:small;padding-left:4px;} (Chris Skedgel)

Publication Activity (10 Years)

Top Topics

Top Venues

Christopher Skedgel (Chris Skedgel)